Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 trial of margetuximab combinations in first-line HER2-positive gastric or gastroesophageal junction cancer
2019-004699-21Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of margetuximab in HER2-positive gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by MacroGenics. Primary endpoint: Incidence of adverse events of margetuximab plus INCMGA00012. Started May 2020; status: terminated.
02
Drugs
margetuximab
03
Conditions
HER2-positive gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2019-004699-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004699-21.